ICI Combination Regimens for First-Line Treatment of Metastatic ESCC
Harry Yoon, MD
Jaffer Ajani, MD
Effective Monitoring and Management of Adverse Effects in Metastatic ESCC
Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC
Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC
The Importance of PD-L1 Testing: Shaping the Future of Treatment in ESCC
Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens for Metastatic ESCC
Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies
The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC
Patient Case Study: Cancer-Associated Thrombosis
Renato D. Lopes, MD, MHS, PhD
Alexander T. Cohen, MD, MBBS
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: AF Considerations
Valeria Caso, MD, PhD
Trade off: Ischemic/Thrombotic vs Bleeding
How Do We Translate Real-World VTE Data Into Everyday Clinical Practice for Ongoing Anticoagulation?
Patient Case Study: Elderly
Patient Case Study: Obesity and VTE
Implications Associated With Integrating Both Real-World Data and Clinical Trial Data Into Clinical Practice: VTE Considerations
Patient Case Study: Obesity
Loading...
We're glad to see you're enjoying MedEd On The Go… but how about a more personalized experience?
Press cancel to remain on MedEd On The Go. Press the link below or the continue button to keep going.